Background/Aims: Limited data exist on long-term dose response to recombinant human growth hormone (rhGH) in prepubertal GH-deficient (GHD) children. The effect of low, intermediate, and high-dose rhGH (25, 50, and 100 μg/kg/day, respectively) on growth and puberty in children with GHD was investigated for 48 months. Methods: A prospective, dose-response study in 111 patients (aged 3-16 years) evaluated growth velocity (cm/year), height standard deviation score (HSDS), corrected HSDS, bone age/chronologic age ratio, body mass index SDS, and the percentage starting puberty. Results: Dose-related increases were observed in growth velocity (p < 0.001), HSDS (p < 0.001), and corrected HSDS (p < 0.001) from baseline to 48 months. Increases in the bone age/chronologic age ratio (p = 0.043) and body mass index SDS (p = 0.018) occurred up to 36 months at intermediate and high doses versus low-dose rhGH; increases at 48 months were not significant. No significant differences in growth were found between intermediate and high doses of rhGH. Percentages of rhGH-treated patients starting puberty at each dose were equivalent (p = 0.607). Conclusions: rhGH, 50 and 100 μg/kg/day, induced greater growth than 25 μg/kg/day without altering the proportion of children starting puberty. The maximum approved dose for pubertal patients (100 μg/kg/day) is not required or recommended for prepubertal children with GHD.

Keywords:
Human growth hormone, Growth hormone-deficient children, Puberty
1.
Richmond E, Rogol AD: Current indications for growth hormone therapy for children and adolescents; in Hindmarsh PC (ed): Current indications for growth hormone therapy. Basel, Karger, 2010, vol 18, pp 92-108.
2.
Wilson TA, Rose SR, Cohen P, Rogol AD, Backeljauw P, Brown R, Hardin DS, Kemp SF, Lawson M, Radovick S, Rosenthal SM, Silverman L, Speiser P: Update of guidelines for the use of growth hormone in children: The Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J Pediatr 2003;143:415-421.
3.
Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J: High-dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group. J Clin Endocrinol Metab 2000;85:3653-3660.
4.
Cohen P, Bright GM, Rogol AD, Kappelgaard AM, Rosenfeld RG: Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: implications for efficacy and safety. J Clin Endocrinol Metab 2002;87:90-98.
5.
Marshall WA, Tanner JM: Variations in pattern of pubertal changes in girls. Arch Dis Child 1969;44:291-303.
6.
Prader A: Testicular size: assessment and clinical importance. Triangle 1966;7:240-243.
7.
Marshall WA, Tanner JM: Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970;45:13-23.
8.
Tanner JM, Davies PS: Clinical longitudinal standards for height and height velocity for North American children. J Pediatr 1985;107:317-329.
9.
Hamill PV, Drizd TA, Johnson CL, Reed RB, Roche AF: NCHS growth curves for children birth-18 years. United States. Vital Health Stat 1977;165:i-iv, 1-74.
10.
National Center for Health Statistics: Growth Curves for Children, Birth-18 Years, United States, DHEW Publ. No. (PHS) 78-1650. Hyattsville, US Department of Health, Education and Welfare, 1977.
11.
Pyle SI, Waterhouse AM, Greulich WW: Attributes of the radiographic standard of reference for the National Health Examination Survey. Am J Phys Anthropol 1971;35:331-337.
12.
Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard AM, Rosenfeld RG: Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. J Clin Endocrinol Metab 2007;92:2480-2486.
13.
Cohen P, Germak J, Rogol AD, Weng W, Kappelgaard AM, Rosenfeld RG: Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children. J Clin Endocrinol Metab 2010;95:2089-2098.
14.
Pawlikowska-Haddal A, Cohen P, Cook DM: How useful are serum IGF-1 measurements for managing GH replacement therapy in adults and children? Pituitary 2012;15:126-134.
15.
Cohen P, Rogol AD, Weng W, Kappelgaard AM, Rosenfeld RG, Germak J: Dose-sparing and safety-enhancing effects of an IGF-1-based dosing regimen in short children treated with growth hormone in a 2-year randomized controlled trial: therapeutic and pharmacoeconomic considerations (Abstract Poster SUN-LB2013). Endocr Rev 2012;33.
16.
Lee PA, Germak J, Gut R, Khutoryansky N, Ross J: Identification of factors associated with good response to growth hormone therapy in children with short stature: results from the ANSWER Program. Int J Pediatr Endocrinol 2011;2011:6.
17.
Roemmich JN, Huerta MG, Sundaresan SM, Rogol AD: Alterations in body composition and fat distribution in growth hormone-deficient prepubertal children during growth hormone therapy. Metabolism 2001;50:537-547.
18.
Radetti G, Buzi F, Paganini C, Martelli C, Adami S: A four year dose-response study of recombinant human growth hormone treatment of growth hormone deficient children: effects on growth, bone growth and bone mineralization. Eur J Endocrinol 2000;142:42-46.
19.
Yokoya S, Araki K, Igarashi Y, Kohno H, Nishi Y, Hasegawa Y, Fujita K, Iwatani N, Tachibana K, Ohyama Y, Seino Y, Satoh M, Fujieda K, Tanaka T: High-dose growth hormone (GH) treatment in prepubertal GH-deficient children. Acta Paediatr 1999;88(suppl):76-79.
20.
Lee PA, Savendahl L, Oliver I, Tauber M, Blankenstein O, Ross J, Snajderova M, Rakov V, Pedersen BT, Christesen HT: Comparison of response to 2-years' growth hormone treatment in children with isolated growth hormone deficiency, born small for gestational age, idiopathic short stature, or multiple pituitary hormone deficiency: combined results from two large observational studies. Int J Pediatr Endocrinol 2012;2012:22.
21.
Ross J, Lee PA, Gut R, Germak J: Factors influencing the one- and two-year growth response in children treated with growth hormone: analysis from an observational study. Int J Pediatr Endocrinol 2010;2010:494656.
22.
Clayton PE, Cuneo RC, Juul A, Monson JP, Shalet SM, Tauber M: Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol 2005;152:165-170.
23.
Leschek EW, Troendle JF, Yanovski JA, Rose SR, Bernstein DB, Cutler GB Jr, Baron J: Effect of growth hormone treatment on testicular function, puberty, and adrenarche in boys with non-growth hormone-deficient short stature: a randomized, double-blind, placebo-controlled trial. J Pediatr 2001;138:406-410.
24.
Albin AK, Ankarberg-Lindgren C, Tuvemo T, Jonsson B, Albertsson-Wikland K, Ritzen EM: Does growth hormone treatment influence pubertal development in short children? Horm Res Paediatr 2011;76:262-272.
25.
Sas TC, de Ridder MA, Wit JM, Rotteveel J, Oostdijk W, Reeser HM, Otten BJ, de Muinck Keizer-Schrama SM: Adult height in children with growth hormone deficiency: a randomized, controlled, growth hormone dose-response trial. Horm Res Paediatr 2010;74:172-181.
26.
Kamp GA, Waelkens JJ, de Muinck Keizer-Schrama SM, Delemarre-Van de Waal HA, Verhoeven-Wind L, Zwinderman AH, Wit JM: High-dose growth hormone treatment induces acceleration of skeletal maturation and an earlier onset of puberty in children with idiopathic short stature. Arch Dis Child 2002;87:215-220.
27.
Kawai M, Momoi T, Yorifuji T, Yamanaka C, Sasaki H, Furusho K: Unfavorable effects of growth hormone therapy on the final height of boys with short stature not caused by growth hormone deficiency. J Pediatr 1997;130:205-209.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.